Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Twenty years ago today, the International Genome Sequencing Consortium published the first detailed analysis of the human genome. The paper appeared online in Nature on 15 February 2001, followed by a ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major ...

The Institute of Cancer Research has welcomed new plans to deliver around one million square feet of state-of-the-art research and laboratory space for life-sciences companies in Sutton, south London, ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma, a common type of adult brain tumour, rely on a specific enzyme for survival and that inhibiting ...

Image: Scanning electron micrograph of a single prostate cancer cell. Credit: Anne Weston, Francis Crick Institute The Institute of Cancer Research, London, has expressed disappointment that NICE has ...

Black men are more likely than their White or Asian counterparts to have a range of genetic changes that increase their risk of developing prostate cancer, a major new study reports. The genetic ...

The last decade has brought major advances in the way we diagnose and treat prostate cancer and men with advanced disease are living longer than ever. Diana Cano spoke to our scientists about the most ...

Every day in the UK, about 1,000 people find out that they have cancer. Most of these people will end up sharing the news with family, friends and colleagues, from whom they will usually receive ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...